Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
ALLO-501 by Allogene Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval
ALLO-501 is under clinical development by Allogene Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...